| abstract |
A compound represented by the following structural formula ** Formula ** or a pharmaceutically acceptable salt thereof, for use in a method of treating a subject with Fabry disease, the method comprising: evaluating the subject to determine if the subject is a poor, intermediate or broad / ultrafast P450 metabolizer, where the subject is assessed as a poor, intermediate or broad / ultrafast P450 metabolizer by genotyping, where a poor P450 metabolizer carries two mutant alleles of the CYP2D6 gene resulting in loss Complete with enzymatic activity, an intermediate P450 metabolizer has one allele with reduced activity and one null allele of the CYP2D6 gene, a broad P450 metabolizer has at least one and no more than two normal functional alleles of the CYP2D6 gene, and a P450 metabolizer. Ultrafast carries multiple copies of functional alleles of the CYP2D6 gene and produces excess enzyme activity; and administering to the subject an adjusted effective amount of the compound if the subject is an intermediate or broad / ultrafast P450 metabolizer and administering to the subject an effective amount of the compound if the subject is a poor P450 metabolizer, wherein said effective amount is a daily dose from 25 milligrams to 300 milligrams, and where said adjusted effective amount is greater than said effective amount. |